Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data

The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.

Gilead and Kite at ASCO 2023 • Source: Alaric DeArment

More from ASCO

More from Conferences